



**2001 6**

\_\_\_\_\_ ( )

\_\_\_\_\_ ( )

\_\_\_\_\_ ( )

\_\_\_\_\_ ( )

\_\_\_\_\_ ( )



	-----	1
.	-----	3
.	-----	6
1.	-----	6
2.	-----	7
가.	-----	7
.	-----	8
.	-----	10
.	-----	10
.	-----	11
.	-----	12
1.	-----	12
2.	-----	14
3.	-----	15
4.	-----	16
.	-----	24
.	-----	29
	-----	31
	-----	34

1.	-----	19
2.	-----	19
3.	-----	20
4.	-----	20
5.	-----	20
6.	-----	21
7.	-----	21
8.	-----	21

1.		-----	6
2.	pH	nyosin ATPase	
		-----	10
3.		-----	22
4.		-----	23

가 , 가  
 가 . 가  
 , 가 .  
 , 가  
 . ,  
 , ( ),  
 ( ) ( )  
 ,  
 .

1. 12 , 13 , 14  
 , 15 . 16  
 가 , 17 가 . 18  
 , 가  
 . 23 가 (pad)가

1  
 2. 가 가 . 가  
 , ,  
 .

3. 17 , 18 .  
 , 가  
 , 21

4. 17 IIc  
 , 17 I 가 28 I  
가 , 31 IIa IIb 가 .  
 ,  
 ,  
 ,  
 IIc I ,  
 I .

---

: , , , , , ,

< >

# I.

,  
1-2  
,  
3-5 (congenital  
myopathy),  
I 가  
6  
가 가

1900

7-10

(parenchymal organ)

Dubowitz<sup>11</sup>

12

, . 1 12

20 , (IIc )가 . 2 20

26 , I II 가 , I 가

. 3 30 ,

, I II .<sup>12</sup>

13-20

, ,

IIc 가 20

I (large type I) , 30 I

가 IIc . IIa IIb

5 , ,

가 Ringqvist<sup>21</sup>

(masticatory muscles) (biceps brachii muscle) ,

22 , 16 가

가

, IIc

I , IIa IIb 가 가

가 .

,

(ventromedial pathway) (anterior funiculus) (lateral funiculus)

(extensor muscle)

(dorsolateral pathway)

(lateral funiculus)

(flexor muscle)

.<sup>22</sup>

Kumagai<sup>18</sup>

femoris muscles) , (psoas muscles) (quadriceps  
, 30 I 가 18 I 가  
20-23%가 50%,

. Elder<sup>23</sup>

, 22 26 I 가 5%,  
13% , 30 가

가

가

가

( ) ( )

## II.

### 1.

55 ( 1). 4 8 24  
가

### 1.

Gestational age(week)	Carnegie stage	Number	Crown rump length(Foot length) (mm)
4	12	2	4.5 / 5.0
	13	2	3.0 / 4.2
5	14	2	6.2 / 6.5
	15	2	7.3 / 9.0
6	16	2	10.7 / 11.7
	17	2	12.9 / 14.0
7	18	2	15.8 / 15.9
	19	2	16.5 / 17.4
8	20	2	18.9 / 22.0
	21	2	20.2 / 22.5
	22	2	23.4 / 23.8
	23	2	25.0 / 28.0
9		2	33 / 43
10		2	51 / 58
11		1	73(13)
12		1	93(14)
13		1	102(18)
15		1	123(26)
17		2	149(29) / 155(31)
18		1	150(34)
19		2	167( - ) / 175(36)
20		3	165(50) / 180(40) / 188(41)
21		3	178(38) / 188(42) / 195(42)
22		1	210(47)
23		3	218(48) / 220(46) / 225(47)
24		1	220(53)
25		1	235(53)
27		1	240(64)
28		2	250(62) / 250(65)
30		1	260(66)
31		1	260(69)
34		1	300(80)

(Carnegie stage)<sup>24</sup>

4 10-13 , 5 14 15 ,  
 6 16 17 , 7 18 19 , 8 20-23  
 9 34 31 , (crown rump  
 length) (foot length) <sup>25</sup>

2.

가.

가 가 가 5-50  
 가 가 (Wild 10, Leica, Swiss)

10%  
 70%, 85%, 95%(2 ) 100%(2 ) 5-20  
 , histoclear xylene

rotary microtome 5-10  $\mu\text{m}$  10%  
 isopropyl alcohol 45 °C  
 silane coating slide glass hematoxylin-eosin(H-E)  
 Trichrome histomount

가  
 가 (triceps brachii muscle)  
 (biceps brachii muscle), (rectus femoris muscle)  
 (biceps femoris muscle), (gastrocnemius muscle)  
 (anterior tibialis muscle)

1)

10% (perfusion) 9 12  
H-E 13 34

isopentane 가 10 -20 °C  
10 μm

H-E ,

periodic acid schiff (PAS) ,  
myofibrillar adenosine triphosphatase (myosin ATPase) reduced nicotinamide  
dinucleotide-tetrazolium reductase (NADH-TR)

2) PAS <sup>26</sup>

, , , 1% periodic acid (Sigma  
Chemical CO, St. Louis, MO, U. S. A.) 5 ,  
5 . Schiff (Merck KGaA,  
Darmstadt, Germany) 10 , 0.5% sodium meta-bisulfate  
2 3 . 10 Harris hematoxylin

3) Myosin ATPase <sup>27, 28</sup>

, 5  
. Tris buffer 1 가 , acid alkaline  
preincubation (pH 4.3, 4.6, 10.4) 15 . tris buffer  
1 2 , 37 °C 45 .  
1% CaCl<sub>2</sub> 30 3 , 2% cobalt chloride 3

alkaline 30 4 . 1% ammonium sulfide  
3 , 5 ,

(1) : 40% 50 ml sodium cacodylate (Wako Pure Chemical Industries Ltd, Tokyo, Japan) 31 g, CaCl<sub>2</sub> 10 g, sucrose 115 g 가  
, 1 l .

(2) Tris buffer : 850 ml, 0.18 M CaCl<sub>2</sub> 100 ml, Tris (hydroxymethyl) aminomethane (Sigma Chemical CO, St. Louis, MO, U. S. A.) 12.1 g  
, 1 N-6 N HCl pH 7.8 1 l

(3) alkaline preincubation : 1.5 M alkaline buffer (2-amino-2-methyl-1-propanol buffer, Sigma Diagnostics Inc, St. Louis, MO, U. S. A.) 3.35 ml, 0.18 M CaCl<sub>2</sub> 10 ml, 35 ml , 1 N-10 N KOH pH 10.4  
50 ml .

(4) : 1.5 M alkaline buffer 3.35 ml, 0.18 M CaCl<sub>2</sub> 5 ml, KCl 185 mg, adenosine-5'-triphosphate disodium salt (ICN Biomedicals Inc, Aurora, Ohio, U. S. A.) 76 mg , 6 N HCl pH 9.4 50 ml  
ml .

(5) alkaline : 1.5 M alkaline buffer 13.4 ml, 160 ml , 1 N-6 N HCl pH 9.4 50 ml .

(6) acid preincubation : 0.18 M CaCl<sub>2</sub> 100 ml, 3 ml, 875 ml  
, 1 N-5 N KOH pH 4.3 4.6  
1 l .

#### 4) Reduced nicotinamide adenine dinucleotide (NADH-TR)

37 °C 20-30 , 1  
. 75%, 85%, 95%, 100% , 0.5%  
safranin(Sigma Chemical CO, St. Louis, MO, U. S. A.) 30

(1) : tris-hydrochloric acid buffer 10 M $\ell$ , nitro blue tetrazolium (Sigma Chemical CO, St. Louis, MO, U. S. A.) 10 mg, NADPH ( $\beta$ -nicotinamide adenine dinucleotide phosphate, reduced form, Sigma Chemical CO, St. Louis, MO, U. S. A.) 4 mg pH 7.4 .

(2) Tris-hydrochloric acid buffer : Tris (hydroxymethyl) aminomethane 6.5 g, concentrated hydrochloric acid 3.34 M $\ell$ , 1  $\ell$  pH 7.4

Cooper <sup>29</sup> NADH-TR I ,  
 IIa IIb , Staron Hikida(1992) myosin  
 ATPase  
 Myosin ATPase pH (preincubation) ,  
 2 .

2. pH myosin ATPase

	pH 10.4	pH 4.3	pH 4.6
Type I	○	●	●
Type IIa	●	○	○
Type IIb	●	○	
Type IIc	●	●	●

, 200

(Optimas Image Analyzer Ver 6.1, Optimas Corporation, Bothell, WA, U. S. A.)

(mm<sup>2</sup>) ,

20

(1×1 mm)

SAS (Ver 6.1, SAS Institute Inc, Raleigh, N. C, U.  
S. A.)

### III.

1.

가.

(upper limb bud) 12  
(dorsocaudal) 8-10  
가 0.5 mm, 0.2 mm, 가 0.1 mm  
13 (1B) 7-11  
가 0.9mm, 가 0.3mm  
14 (1C) 가 가  
15 (1D)  
(hand plate)  
(hand segment)  
16 (1E) 가  
(digital plate) 17 (1F)  
(finger ray)가 17  
18 (1G) 가  
(interdigital notch) 가  
19 (1H) 가  
20 -23 가 20  
가

21 가 , 22 가  
 . 23 가  
 (pad)가 ( II).  
 ( I) 가 가 , 가  
 ,  
 .  
 .  
 (lower limb bud) 13 ( , 24-27  
 2A).  
 가 0.5 mm, 가 0.2 mm .  
 14 ( 2B) 가 0.7 mm 가 0.3 mm  
 . 15 ( 2C) 가 1.1 mm  
 가 1.3 mm ,  
 .  
 16 ( 2D) (foot plate) ,  
 . 17 ( 2E)  
 ,  
 .  
 18 ( 2F) (toe ray)가 . 19 ( ,  
 2G) 가 .  
 20 -23 가 . 20  
 , 가 . 21 가  
 . 22 가 , 23 ( 2H) 가  
 (pad)가 .  
 ( 2I) 가 가 ,  
 가 ,  
 .

2.

가.

12 ( 3A) (surface ectoderm)  
.  
, 2-3 (ectodermal thickening) .  
13 ( 3B)  
가  
,  
14 ( 3C) (apical  
ectodermal ridge) ,  
(brachial plexus)  
, 가 가 15 ( 3D)  
, ,  
가 가  
16 ( 3E) (mesenchymal  
primordium) , ,  
가 .  
17 , ,  
가 .  
.  
13 ( 4A) ,  
2-3 가 , .  
.

14 ( 4B) ,  
가 . 15 ( 4C)

16 ,  
. 17 ( 4D) ,

18 .

3.

가.

17 ( 5A, B) ,  
. ,  
 ,  
 ,

18 ( 5C, D) 가

19 가 가

8 , 22  
( 5E, F). 10 ( 5H)가  
( 5I).

18 ( 6A)

가 , 19  
가 , (femoral condyle) (tibial condyle)

가

가  
20 ( 6B) ( 6C)

21 ( 6D) 가 22  
( 6E, F) 10  
가 가

4.

가.

( 7A, B).  
21 ( C, D, E)가

17

( 8A) IIc 17 ( 8B) I 가 28 ( 8C) I 가 , 31 ( 8D) IIa IIb 가 .

3

IIb (p<0.05)  
IIb I (p<0.01).  
IIc 17-27  
(p<0.01), I 17-27  
(p<0.01) I 28-30  
(p<0.05).

4

(p<0.05)  
(p<0.01).  
IIc I (p<0.01) I  
(p<0.01) I (p<0.01).  
, IIc 16  
(p<0.01) (p<0.05).  
17-27 (p<0.01)  
(p<0.01). 28-30 (p<0.01)  
(p<0.01) (p<0.01). 31  
(p<0.05)

(p<0.05).

I

17-27

(p<0.01)

(p<0.01),

(p<0.05)

(p<0.01)

(p<0.01).

28-30

(p<0.01)

(p<0.01)

(p<0.01).

(p<0.01),

(p<0.01).

I

28-30

(p<0.01)

(p<0.01).

31

(p<0.01)

(p<0.01),

(p<0.05).




그림 1 상지의 외형 발달. A. 발생 12기 B. 발생 13기 C. 발생 14기 D. 발생 15기  
E. 발생 16기 F. 발생 17기 G. 발생 18기 H. 발생 19기 I. 발생 23기  
J. 발생 9주




그림 2 하지의 외형 발달. A. 발생 13기 B. 발생 14기 C. 발생 15기 D. 발생 16기  
E. 발생 17기 F. 발생 18기 G. 발생 19기 H. 발생 23기 I. 발생 9주




그림 3 상지의 초기 조직발생. A. 발생 12기 B. 발생 13기 C. 발생 14기 D. 발생 15기 E. 발생 16기




그림 4 하지의 초기 조직발생. A. 발생 13기 B. 발생 14기 C. 발생 15기 D. 발생 17기




그림 5 상지 근육의 초기 발생. A. 발생 17기 상지의 저배율 단면 B. A에 표시된 각각 부위의 고배율 사진 C. 발생 18기 상지의 저배율 단면 D. C에 표시된 각각 부위의 고배율 사진 E. 발생 22기 상지의 저배율 단면 F. E에 표시된 각각 부위의 고배율 사진 G. 발생 23기 상지의 단면 H. 발생 12기 태아의 상완이두근 I. 발생 20기 태아의 상완이두근. TB; 상완삼두근, BB; 상완이두근




그림 6 하지 근육의 초기 발생. A. 발생 18기 하지의 단면 B. 발생 20기 대퇴의 조직 단면 C. 발생 20기 하퇴의 조직 단면 D. 발생 21기 하지의 조직 단면 E. 발생 22기 대퇴의 조직 단면 F. 발생 22기 하퇴의 조직 단면. QF; 대퇴사두근, PF; 후대퇴근, BF; 대퇴이두근, GC; 비복근, TA; 전경골근




그림 7 태아기 중 근육의 초기 분화. A. 발생 13주 B. 발생 17주 C. 발생 24주 D. 발생 27주 E. 발생 31주




그림 8 태아기 중 근섬유형의 출현. A. 발생 13주 B. 발생 17주 C. 28주 D. 발생 31주

표 3 발생에 따른 근섬유형의 발현(%)

IIc : 미분화 섬유, LI : 큰 I형 섬유, I : I형 섬유, IIa : IIa형 섬유, IIb : IIb형 섬유

근육	Week	13	15	17	18	19	20	21	22	23	24	25	27	28	30	31	34
	섬유형																
triceps brachii	IIc	100	100	98.3	96	97.3	95.4	94.1	97	93.4	94	90	89	94	90.3	64.7	42.3
	LI			1.7	4	2.7	4.6	5.9	3	6.6	6	10	11	5.3	8	2.3	2.3
	I													0.7	1.7	20	31
	IIa															12	19.3
	IIb															1	5
biceps brachii	IIc	100	100	97.7	98	97.3	94.7	93.8	93	94.7	97	95	85	90.8	88.3	65.3	41.7
	LI			2.3	2	2.7	5.3	6.2	7	5.3	3	5	15	8	9	3.3	2.7
	I													1.2	2.7	18	32.3
	IIa															9.7	18.7
	IIb															3.7	4.7
rectus femoris	IIc	100	100	99	99	98.3	95.9	93	91	92.9	95	96	94	91.5	88	64.7	41.7
	LI			1	1	1.7	4.1	7	9	7.1	5	4	6	7.3	9	3	2
	I													1.2	3	18	31.3
	IIa															10.7	20
	IIb															3.7	5
biceps femoris	IIc	100	100	98	97	97	96.2	93.1	92	91.2	96	94	93	91.8	87.3	64.7	40.7
	LI			2	3	3	3.8	6.9	8	8.8	4	6	7	7.3	9.7	2.3	3
	I													0.9	3	20	33
	IIa															12	19
	IIb															1	4.3
tibialis anterior	IIc	100	100	98.3	98	97.7	95	91.8	89	91.3	89	94	92	88	88	65.3	42.3
	LI			1.7	2	2.3	5	8.2	11	8.7	11	6	8	11	7.3	3.3	2.3
	I													1	4.7	18	31
	IIa															9.7	19.3
	IIb															3.7	5
gastrocnemius	IIc	100	100	97.5	99	97.5	95.4	89.9	88	90.4	96	93	93	90.8	88.7	64.7	41.3
	LI			2.5	1	2.5	4.6	10.1	12	9.6	4	7	7	8	9.3	3	2.3
	I													1.2	2	18	31
	IIa															10.7	20.3
	IIb															3.7	5

표 4 섬유형에 따른 근섬유의 면적( $\mu\text{m}^2$ )

IIc : 미분화 섬유, LI : 큰 I형 섬유, I : I형 섬유, IIa : IIa형 섬유, IIb : IIb형 섬유

근육	Week	13	15	17	18	19	20	21	22	23	24	25	27	28	30	31	34
	섬유형																
triceps brachii	IIc	80.0	89.2	76.8	87.5	92.6	76.8	72.9	74.3	75.8	74.3	77.5	85.4	102.4	109.0	100.8	131.7
	LI			156.3	172.1	149.5	144.1	144.3	135.4	175.3	163.7	156.6	166.5	234.3	171.3	172.1	183.7
	I													84.4	87.7	90.6	105.1
	IIa															140.7	172.3
	IIb															140.0	171.4
biceps brachii	IIc	83.5	90.6	78.5	72.6	84.0	77.5	68.2	73.8	73.2	75.4	72.5	95.1	102.0	107.9	93.8	127.8
	LI			150.1	140.0	127.4	146.4	135.1	135.6	162.9	154.6	137.1	183.6	210.9	171.7	174.4	182.2
	I													71.4	86.8	118.2	100.9
	IIa															149.4	174.4
	IIb															142.7	170.9
rectus femoris	IIc	82.1	74.4	79.9	72.3	78.0	72.9	68.4	69.4	71.4	77.0	74.7	86.3	97.6	96.7	101.9	125.9
	LI			156.2	125.9	128.1	134.2	131.9	131.9	161.9	153.7	145.8	172.7	179.4	176.3	170.7	180.0
	I													64.9	96.5	118.5	102.4
	IIa															146.8	171.6
	IIb															146.2	172.6
biceps femoris	IIc	76.8	80.3	75.6	74.8	85.6	77.1	65.2	69.6	70.0	75.8	74.3	90.6	103.3	95.0	106.3	131.7
	LI			136.7	122.9	144.0	143.4	126.1	137.7	157.0	152.0	147.3	174.3	224.7	171.9	173.2	183.5
	I													70.2	84.7	104.6	110.2
	IIa															146.2	174.0
	IIb															145.1	172.1
tibialis anterior	IIc	77.6	82.2	78.1	66.5	78.6	74.4	67.5	70.4	73.3	74.2	73.3	79.9	95.2	106.3	90.6	133.2
	LI			142.8	142.7	134.7	152.3	130.3	129.4	147.4	155.5	145.7	169.9	188.3	183.6	172.6	184.4
	I													70.4	87.0	118.7	93.8
	IIa															143.2	172.6
	IIb															142.9	171.1
gastrocnemius	IIc	68.6	93.8	79.3	72.4	79.3	72.8	68.5	68.0	72.0	74.4	174.2	81.0	104.0	106.9	105.4	137.8
	LI			145.0	131.7	134.4	131.7	132.0	129.7	136.8	164.9	141.4	167.0	197.3	167.2	70.9	180.3
	I													69.5	86.3	113.9	90.6
	IIa															138.5	174.3
	IIb															138.4	173.8

#### IV.

가 7-10  
가 11  
가 3-5  
가 12-20  
Ilc  
가 18-23  
( )  
가  
( )  
( )  
( )

24,30

Iffy

25

I

II

myosin ATPase

I

II

10 μm

가

13

, ( ) , ( ) , ( ) ,  
가

31-33

mesoderm)

(somatic

가

34

35

가

36

12

13

,

15

16

가

17

가

가

가 . ,

가

(myoblast) , 가 (myotube)

가

가 (presumptive myoblast) .

가 (postmitotic myoblast) .

17

가 (marker)

가 가

7 - 9

<sup>37</sup> 가

hematoxylin eosin ,

17 18 8

10

10-15

가 16

13

17

24 가

I Ic 30 I 20  
 가 Ic IIa IIb  
 5 , 가 Ringqvist <sup>21</sup>  
 16 가 22 , 가

가

가

가

27-28

I 가 28-45%, Ic  
 가 10-17% .<sup>38</sup> 가 I 5  
 8-10 70% 18  
 I  
 5 38-45% 가 가  
 Ic 가 5%  
 가  
 가 ,  
 가

·  
·  
,  
,  
( ),  
( )  
가  
·  
가  
·  
·  
가

## V.

,  
( ), ( ) ( )  
) ,

1. 12 , 13 , 14  
, 15 . 16  
가 , 17 가 . 18  
, 가  
. 23 가 (pad)가

1  
2. ,  
가 가 . 가

3. 17 , 18 .  
, 가  
. , 21

4. 17 Ilc

가 , 17 I 가 28 I  
가 , 31 IIa IIb 가 .  
 , , , .  
 , .  
 IIc I ,  
 I .

1. Kimura J. *Electrodiagnosis in Diseases of Nerve and Muscle: Principles and Practice*. 2nd ed. F. A. Davis Company; 1989.
2. Delisa JA, Gans BM. *Rehabilitation Medicine: Principles and Practice* 2nd ed. J. B. Lippincott Company; 1993.
3. Karpati G, Engel WK. "Type grouping" in skeletal muscles after experimental reinnervation. *Neurology* 1968; 18: 447-455.
4. Lomo T, Westgaard RH, Dahl HA. Contractile properties of muscle: Control by pattern of muscle activity in the rat. *Proc R Soc Lond [Biol]* 1974; 187: 99-103.
5. Romanul FCA, Van Der Meulen JP. Slow and fast muscles after cross innervation: enzymatic and physiological changes. *Arch Neurol* 1967; 17: 387-402.
6. Banker BQ. The congenital myopathies. In : Engel AG, Banker BQ(eds): *Myology*. New York: McGraw-Hill; 1986, pp1527-1581.
7. MacCallum JB. On the histogenesis of the striated muscle fibre, and the growth of the human sartorius muscle. *Johns Hopk Hosp Bull* 1898; 9: 208-215.
8. Bardeen CR, Lewis WH. Development of the limbs, body-wall and back in man. *Am J Anat* 1901-2; 1: 1-36.
9. Lewis WH. The development of the arm in man. *Am J Anat* 1901-2; 1: 145-183.
10. Bardeen CR. Development and variation of the nerves and the musculature of the inferior extremity and of the neighboring regions of the trunk in man. *Am J Anat* 1906-7; 6: 259-390.
11. Dubowitz V. Histochemistry, enzyme histochemistry of developing human muscle. *Nature* 1966; 211: 884-885.
12. Brooke MH, Williamson E, Kaiser KK. The behavior of four fiber types in developing and reinnervated muscle. *Arch Neurol* 1971; 25: 360-366.
13. Engel WK. Fiber-type nomenclature of human skeletal muscle for histochemical purposes. *Neurology* 1974; 24: 344-348.

14. Farkas-Bargeton E, Diebler MF, Arsenio-Nunes ML, Wehrle R, Rosenberg B. Etude de la maturation histochemique, quantitative et ultrastructurale du muscle foetal humain. *J Neurol Sci* 1977; 31: 245-259.
15. Colling-Saltin AF. Enzyme histochemistry on skeletal muscle of the human fetus. *J Neurol Sci* 1978; 39: 169-185.
16. Billeter R, Heizmann CW, Howald H, Jenny E. Analysis of myosine light and heavy chain types in single human skeletal muscle fibers. *Europ J Biochem* 1981; 116: 389-395.
17. Thornell LE, Billeter R, Butler-Browne GS, Eriksson PO, Ringqvist M, Whalen RG. Development of fiber types in human fetal muscle. *J Neurol Sci* 1984; 66: 107-115.
18. Kumagai T, Hakamada S, Hara K, Takeuchi T, Miyazaki S. Development of human fetal muscle: A comparative histochemical analysis of the psoas and the quadriceps muscles. *Neuropediatrics* 1984; 15: 198-202.
19. Pons F, Léger JOC, Chevallay M, Tomé FMS, Fardeau M, Léger JJ. Immunocytochemical analysis of myosin heavy chains in human fetal skeletal muscles. *J Neurol Sci* 1986; 76: 151-163.
20. Draeger A, Weeds AG, Fitzsimons RB. Primary, secondary and tertiary myotubes in developing skeletal muscle: A new approach to the analysis of human myogenesis. *J Neurol Sci* 1987; 81: 19-43.
21. Ringqvist M, Ringqvist I, Thornell LE. Differentiation of fibers in human masseter, temporal and biceps brachii muscles. *J Neurol Sci* 1977; 32: 265-273.
22. Davidoff RA. The pyramidal tract. *Neurlogy* 1990; 40: 332-339.
23. Elder GCB, Kakulas BA. Histochemical and contractile property changes during human muscle development. *Muscle and Nerve* 1993; 16: 1246-1253.
24. O'Rahilly R, Müller F. *Developmental Stages in Human Embryos*. Carnegie Institution of Washington, 1987.
25. Iffy L, Jakobovits A, Westlake W, Wingate M, Caterini H, Karofsky P, Menduke H. Early intrauterine development: I. The rate of growth of caucasian embryos and fetuses between the 6th and 20th weeks of gestation. *Pediatrics* 1975; 56: 173-186.
26. Sheehan DC, Hrapchak BB. *Theory and Practice of Histotechnology*. London: The C. V. Mosby Company; 1980. p.162
27. Guth L, Samaha FJ. Procedure for the histochemical demonstration of actomyosin ATPase. *Exp Neurol* 1970; 28: 365-367.

28. Staron RS, Hikida RS, Hagerman FC. Myofibrillar ATPase activity in human fast-twitch subtypes. *Histochemistry* 1983; 78: 405-408.
29. Cooper CC, Cassens RG, Kastenschmidt LL, Briskey EJ. Histochemical characterization of muscle differentiation. *Dev Biol* 1970; 23: 169-184
30. , , . , .  
1992; 25: 1-11.
31. Olivier G. Formation du squelette des membres chez l'homme. Paris: Vigot; 1962
32. Blechschmidt E. The early stages of human limb development. In: *Limb Development and Deformity*(Swinyard CA, ed). Thomas, Springfield, 1969; pp 24-56.
33. O'Rahilly R, Gardner E. The timing and sequence of events in the development of the limbs in the human embryo. *Anat Embryol* 1975; 148: 1-23.
34. Saunders JW, Gasseling MT, Errick JE. Inductive activity and enduring cellular constitution of a supernumerary apical ectodermal ridge grafted to the limb bud of the chick embryo. *Dev Biol* 1970; 50: 16-25.
35. O'Rahilly R, Gardner E, Gray DJ. The ectodermal thickening and ridge in the limbs of staged human embryos. *J Embryol Exp Morphol* 1956; 4: 254-264.
36. Vivarelli E, Cossu G. Neural control of early myogenic differentiation in cultures of mouse somites. *Dev Biol* 1986; 117: 319-325.
37. Tomanek RJ, Colling-Saltin A. Cytological differentiation of human fetal skeletal muscle. *Am J Anat* 1977; 149: 227-246.
38. Elder GCB, Kakulas BA: Histochemical and contractile property changes during human muscle development. *Muscle & Nerve* 1993; 16: 1246-1253.

## ABSTRACT

# Early Development and Differentiation of Muscles in Developing Human Limbs

**Joon Hwan Kim**

Brain Korea 21 Project for Medical Sciences

The Graduate School, Yonsei University

(Directed by Professor Hyoung Woo Park)

This study was performed to know the differentiation of fiber types in developing human skeletal muscles of the extremities.

The material consisted of muscle samples from different muscles, i. e. biceps brachii, triceps brachii, quadriceps femoris, biceps femoris, tibialis anterior, and gastrocnemius, of 55 fetuses between 4 and 34 week of development.

Serial crossly cut frozen sections of different 6 muscles were stained with H-E, PAS, Masson's trichrome, NADH-TR, myofibrillar ATPase(preincubation at PH 4.3, 4.6, 10.3 ) and analyzed quantitatively as well as qualitatively.

The results are as follows :

1. By the end of the stage 12, the upper limb was observed as small elevation. The lower limb bud appeared one stage later. With further growth, the upper and lower limbs became adult shape.
2. The limb buds consisted of a core of mesenchyme and a covering layer of the ectoderm. At the apex of the buds, the ectoderm was somewhat thickened and was known as the apical ectodermal ridge. Blood vessels were developed first and various

spinal nerves penetrated into the mesenchyme, then osseous components were developed and finally limb musculature was found.

3. The first identification of the upper limb musculature was found at stage 17. The lower limb musculature appeared at stage 18.
4. All muscles consisted of undifferentiated type IIc fibers before the 17th week of development. Large type I fiber began to appear around 17th week. Type I fibers appeared around the 28th week. Type IIa and IIb fibers appeared around the 31th week. The timing of the fiber type expression was equal to all 6 muscles and there were no differences in percentage of fiber types except a few cases. When muscle fiber size was measured at each developmental stage without consideration of fiber types, fiber size of extensor was larger than flexor muscle of the upper extremity. Also larger in extensor muscle of upper extremity than in extensor muscle of the thigh. Type IIc and large type I fibers were larger in extensor muscle than in flexor muscle of the upper extremity and large type I fibers of flexor muscles of lower extremity are larger than those of extensor of lower extremity.

---

Key word : human, embryo, fetus, myogenesis, muscle growth, differentiation